| Drug Name |
Tiludronate disodium |
| Drug ID |
BADD_D02218 |
| Description |
Tiludronate, or (4-chlorophenyl)thio-methylene-1,1-bisphosphonate, is a first generation bisphosphonate similar to [etidronic acid] and [clodronic acid].[A1923,A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification.[A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235]
Tiludronic acid was granted FDA approval on 7 March 1997.[L4763] |
| Indications and Usage |
Tiludronic acid is indicated to treat Paget's disease of bone in patients with serum alkaline phosphatase levels ≥2 times the upper limit of normal, with symptoms, or with risk of future complications.[L4763] |
| Marketing Status |
approved; investigational; vet_approved |
| ATC Code |
M05BA05 |
| DrugBank ID |
DB01133
|
| KEGG ID |
D02285
|
| MeSH ID |
C058651
|
| PubChem ID |
60936
|
| TTD Drug ID |
D0Q8CS
|
| NDC Product Code |
Not Available |
| UNII |
BH6M93CIA0
|
| Synonyms |
tiludronic acid | (4-chlorophenyl)thiomethylene bisphosphonic acid | Cl2SMBP | tiludronate | (chloro-4-phenyl)thiomethylene biphosphonate | (chloro-4-phenyl)thiomethylene bisphosphonate | tiludronate disodium | Skelid |
